Table 1 Baseline clinical characteristics of patients according to SARS-CoV-2 RNA detection in blood by Roche technique.
Study population (n = 193) | Viremia | |||
|---|---|---|---|---|
Absent (n = 100) | Present (n = 93) | P Value | ||
Age | 63 (55–71) | 61 (54–68) | 67 (59–73) | 0.001 |
Male sex | 134 (69) | 68 (68) | 66 (71) | 0.655 |
Comorbidities | 137 (71) | 67 (67) | 70 (75) | 0.206 |
Duration of symptoms at admission (days) | 6 (4–8) | 7 (5–9) | 6 (4–8) | 0.120 |
Baseline PaO2/FiO2 | 188 (100–282) | 250 (145–348) | 146 (90–214) | < 0.001 |
Treatment during hospitalization | ||||
Hydroxychloroquine | 186 (96) | 97(97) | 89(96) | 0.629 |
Lopinavir/ritonavir | 168 (87) | 83 (83) | 85 (91) | 0.083 |
Azithromycin | 133 (69) | 69 (69) | 64 (69) | 0.978 |
Interferon-β | 8 (4) | 2 (2) | 6 (6) | 0.121 |
Glucocorticoids | 134 (69) | 62 (62) | 72 (77) | 0.020 |
Methylprednisolone bolus | 101 (63) | 42 (53) | 59 (72) | 0.014 |
Tocilizumab | 91 (47) | 36 (36) | 55 (59) | 0.001 |
Laboratory findings | ||||
WBC (103/mm3) NR: 4.00–10.00 | 7.18 (4.82–9.61) | 6.89 (4.66–9.35) | 7.47 (5.00–10.36) | 0.374 |
Lymphocytes/mm3 NR: 1.00–4.00 | 790 (590–1165) | 950 (720–1270) | 660 (510–860) | < 0.001 |
Creatinine (mg/dl) NR:0.70–1.20 | 0.86 (0.67–1.09) | 0.85 (0.69–1.03) | 0.90 (0.63–1.16) | 0.563 |
LDH (U/L) NR: 135–225 | 390 (278–512) | 314 (246–428) | 461 (371–565) | < 0.001 |
CK (U/L) NR: 20–180 | 100 (49–270) | 94 (49–155) | 110 (56–336) | 0.315 |
Serum IL-6 (pg/ml) NR: < 30 pg/ml | 20.7 (7.9–52.1) | 16.4 (7.5–41.3) | 27.0 (7.9–70.3) | 0.031 |
Ferritin (ng/ml) NR: 30–400 | 1542 (871–2617) | 1418 (717–2068) | 1637 (944–3088) | 0.267 |
CRP (mg/dL) NR: 0.00–0.50 | 12.2 (5.5–23.0) | 10.3 (5.1–19.2) | 14.7 (7.5–25.7) | 0.026 |
PCT (ng/ml) NR: 0.05–0.09 | 0.19 (0.11–0.41) | 0.13 (0.08–0.31) | 0.26 (0.14–0.56) | 0.002 |
d-dimer (µg/ml) NR:0.14–0.50 | 0.78 (0.52–1.47) | 0.7 (0.45–1.22) | 0.87 (0.67–1.75) | 0.030 |
